2-Picolinic Acid

2-Picolinic Acid

SCHEMBL432468

O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[V+5]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.64
CES1 P23141 1/20 0.64
L3MBTL1 Q9Y468 3/20 0.61
LMNA P02545 3/20 0.61
P4HTM Q9NXG6 2/20 0.61
NAPRT Q6XQN6 1/20 0.61
ALDH1A1 P00352 2/20 0.59
KMT2A Q03164 1/20 0.55
GSK3B P49841 1/20 0.53
KDM4E B2RXH2 4/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL6097337 0.98 CES2 (0.61) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL11378795 0.98 CES2 (0.67) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL524041 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL6054281 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL15401421 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL432467 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL2483447 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5354659 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL5058098 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM
2-Picolinic Acid SCHEMBL673572 0.95 CES2 (0.64) CES2CES1L3MBTL1LMNAP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116111047-B Pyridine vanadium complex modified sodium metal anode and preparation method thereof 广东工业大学 2025-03-28 CN claimed
CN-116111047-A Pyridine vanadium complex modified sodium metal anode and preparation method thereof 广东工业大学 2023-05-12 CN claimed
CN-101229218-B Vanadium compounds for curing diabetes and preparing method thereof SHENZHEN PUTAILUO BIOLOG TECHNOLOGY CO LTD 2010-12-01 CN claimed
CN-101229218-A Vanadium compounds for curing diabetes and preparing method thereof SHENZHEN PUTAILUO BIOLOG TECHN (CN) 2008-07-30 CN claimed
EP-1461328-B1 ORGANIC CHEMICAL OXIDATION DURING HYDROGEN PEROXIDE PRODUCTION ZHOU BING (US) 2007-01-10 EP claimed
EP-1411965-A4 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION NOVACTYL INC (US) 2006-01-11 EP claimed
EP-1461328-A4 ORGANIC CHEMICAL OXIDATION DURING HYDROGEN PEROXIDE PRODUCTION ZHOU BING (US) 2005-06-08 EP claimed
EP-1461328-A1 ORGANIC CHEMICAL OXIDATION DURING HYDROGEN PEROXIDE PRODUCTION Zhou, Bing (US) 2004-09-29 EP claimed
EP-1411965-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION Novactyl, Inc. (US) 2004-04-28 EP claimed
WO-2004009570-A1 ORGANIC CHEMICAL OXIDATION DURING HYDROGEN PEROXIDE PRODUCTION HYDROCARBON TECHNOLOGIES, INC. (US) 2004-01-29 WO claimed
US-20040018143-A1 Hydrogen peroxide production using catalyst particles with controlled surface coordination number HYDROCARBON TECHNOLOGIES INC. 2004-01-29 US claimed
WO-2003006044-A1 METHODS AND COMPOSITIONS FOR CONTROLLING PROTEIN ASSEMBLY OR AGGREGATION NOVACTYL, INC. (US) 2003-01-23 WO claimed
US-6500969-B1 IN SITU PRODUCTION OF OXIDIZER FROM HYDROGEN AND OXYGEN AND OXIDATION OF ORGANIC CHEMICALS IN CONTACT WITH NANOMETER SIZED CRYSTALS OF SUPPORTED NOBLE METAL CATALYST HYDROCARBON TECHNOLOGIES, INC. 2002-12-31 US claimed
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation NOVACTYL, INC. 2002-03-28 US claimed
US-20250255920-A1 Controlled-Release and Stratified Cyclodextrin Inclusion Complex Vehicles CZAP RES AND DEVELOPMENT LLC (US) 2025-08-14 US disclosed
US-12285455-B2 Controlled-release and stratified cyclodextrin inclusion complex vehicles CZAP RESERACH AND DEVELOPMENT, LLC (US) 2025-04-29 US disclosed
CN-116111047-B Pyridine vanadium complex modified sodium metal anode and preparation method thereof 广东工业大学 2025-03-28 CN disclosed
EP-0514451-B1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS LIFESCIENCE CORP (US) 1997-01-15 EP disclosed
EP-0514451-A1 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. UNIV TEXAS (US) 1992-11-25 EP disclosed
WO-1991011117-A2 DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037908-A1 Methods and compositions for controlling protein assembly or aggregation PSEN1, PSEN2, PRNP CES2 4028/4885CES1 4539/4885L3MBTL1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.